Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 55 | 61 | 67 | 60 | 65 | 73 | 79 | 78 | 81 | 88 |
| Expenses | 39 | 36 | 36 | 40 | 44 | 41 | 46 | 49 | 55 | 55 | 57 | 57 |
| Operating Profit | 21 | 15 | 19 | 21 | 23 | 18 | 19 | 24 | 24 | 23 | 24 | 30 |
| OPM % | 35% | 30% | 35% | 34% | 35% | 31% | 29% | 33% | 31% | 30% | 30% | 35% |
| Other Income | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 |
| Depreciation | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 11 |
| Profit before tax | 11 | 6 | 9 | 11 | 14 | 8 | 9 | 12 | 12 | 10 | 10 | 17 |
| Tax % | 24% | 27% | 32% | 27% | 26% | 26% | 22% | 26% | 27% | 28% | 38% | 22% |
| Net Profit | 8 | 5 | 6 | 8 | 10 | 6 | 7 | 9 | 9 | 7 | 6 | 13 |
| EPS in Rs | 121.88 | 67.39 | 94.49 | 1.84 | 2.40 | 1.18 | 1.42 | 1.80 | 1.73 | 1.44 | 1.21 | 2.50 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 158 | 140 | 223 | 190 | 219 | 252 | 310 | 325 |
| Expenses | 123 | 115 | 174 | 143 | 146 | 170 | 214 | 223 |
| Operating Profit | 34 | 25 | 49 | 47 | 73 | 82 | 96 | 102 |
| OPM % | 22% | 18% | 22% | 25% | 33% | 33% | 31% | 31% |
| Other Income | 2 | -1 | 1 | 1 | 1 | 4 | 3 | 3 |
| Interest | 2 | 2 | 2 | 10 | 10 | 9 | 13 | 14 |
| Depreciation | 13 | 16 | 15 | 32 | 33 | 35 | 41 | 43 |
| Profit before tax | 21 | 6 | 33 | 7 | 31 | 41 | 45 | 49 |
| Tax % | 28% | -1% | 28% | 10% | 26% | 25% | 30% | |
| Net Profit | 15 | 6 | 24 | 6 | 23 | 31 | 31 | 35 |
| EPS in Rs | 220.43 | 93.33 | 344.20 | 94.49 | 342.46 | 6.11 | 6.18 | 6.88 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 1% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 17% | 18% | 23% | ||
| Compounded Profit Growth | % | 32% | 62% | 8% | ||
| Stock Price CAGR | % | % | % | 19% | ||
| Return on Equity | % | 14% | 15% | 14% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 10 | 10 |
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 | 234 |
| Borrowings | 13 | 18 | 21 | 99 | 92 | 89 | 130 |
| Other Liabilities | 42 | 28 | 32 | 28 | 30 | 33 | 73 |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 | 448 |
| Fixed Assets | 128 | 119 | 119 | 195 | 212 | 223 | 315 |
| CWIP | 0 | 0 | 1 | 2 | 1 | 11 | 37 |
| Investments | 5 | 5 | 0 | 0 | 0 | 1 | 0 |
| Other Assets | 39 | 46 | 80 | 84 | 87 | 99 | 97 |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 334 | 448 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 31 | 24 | 42 | 44 | 60 | 63 | 82 |
| Cash from Investing Activity | -20 | -28 | -44 | -21 | -35 | -40 | -52 |
| Cash from Financing Activity | -10 | 3 | 1 | -24 | -25 | -24 | -29 |
| Net Cash Flow | 1 | -1 | -0 | -1 | 0 | -0 | 1 |
| Free Cash Flow | 15 | 8 | 23 | 32 | 18 | 21 | 15 |
| CFO/OP | 111% | 100% | 95% | 109% | 95% | 90% | 99% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 14 | 16 | 12 | 9 | 15 | 20 | 27 |
| Inventory Days | 93 | 62 | 38 | 82 | 89 | 100 | 81 |
| Days Payable | 227 | 177 | 84 | 187 | 193 | 169 | 209 |
| Cash Conversion Cycle | -120 | -99 | -34 | -96 | -89 | -49 | -101 |
| Working Capital Days | -35 | -19 | -15 | -49 | -37 | -23 | -28 |
| ROCE % | 8% | 24% | 9% | 17% | 18% | 17% |
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 48.78% | 48.78% | 48.89% | 48.98% | 49.00% | 49.10% | 49.10% |
| FIIs | 15.39% | 14.46% | 13.95% | 13.73% | 13.46% | 13.46% | 13.47% |
| DIIs | 20.43% | 22.05% | 22.37% | 21.98% | 22.57% | 23.14% | 23.22% |
| Public | 15.39% | 14.71% | 14.79% | 15.30% | 14.98% | 14.31% | 14.20% |
| No. of Shareholders | 98,662 | 87,275 | 79,670 | 75,304 | 70,963 | 67,107 | 64,866 |
Fundamentals
Market Cap₹ 1,847 Cr.
Current Price₹ 355
Stock P/E51.6
Book Value₹ 47.0
ROCE17.3 %
ROE14.2 %
Dividend Yield0.14 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)23%
Compounded Profit Growth (TTM)8%
Consolidated figures.
Valuation
Market capRs 1,822 Cr
Enterprise valueRs 1,865 Cr
P/E (TTM)50.88x
Price to book11.80x
Price to sales5.60x
EV / EBITDA17.69x
EV / EBIT29.98x
EV / sales5.73x
Price to cash flow41.30x
Earnings yield1.97%
Profitability
Operating margin (excl. other income)24.65%
Operating margin (incl. other income)25.24%
EBITDA margin32.40%
Pre-tax margin14.94%
Net profit margin11.00%
Net margin, latest quarter14.84%
ROE4.31%
ROCE7.73%
ROA2.71%
ROE, 3-year average9.01%
ROCE, 3-year average12.14%
ROA, 3-year average6.41%
ROIC (approx.)28.28%
Tax rate10.07%
Other income / net worth0.73%
Growth
Sales growth (latest year)-14.81%
Profit growth (latest year)-72.55%
Sales CAGR, 3 years6.48%
Profit CAGR, 3 years-24.60%
Sales growth QoQ7.66%
Profit growth QoQ107.17%
Sales growth YoY (latest quarter)20.75%
Profit growth YoY (latest quarter)38.40%
Per share
EPS (TTM)Rs 6.88
EPS (latest year)Rs 9.45
EPS (latest quarter)Rs 2.50
EPS, 3-year averageRs 149.00
Book value per shareRs 29.66
Sales per shareRs 62.57
Cash flow per shareRs 8.48
Free cash flow per shareRs 2.88
Efficiency
Asset turnover0.68x
Fixed asset turnover0.97x
Inventory turnover7.12x
Inventory days51 days
Debtor days9 days
Debtors turnover40.63x
Creditor days209 days
Cash conversion cycle-101 days
Working capital days-28 days
Leverage
Total debtRs 99 Cr
Cash and bankRs 55 Cr
Net debtRs 43 Cr
Debt to equity0.64x
Net debt / EBITDA0.41x
Interest coverage4.58x
Current ratio (filing 2026-03-31)1.05x
Quick ratio (filing 2026-03-31)0.91x
Trade payables (filing 2026-03-31)Rs 21 Cr
Owners' fund to total sources54.88%
Debt to assets35.03%
Cash flow
Cash from Operating Activity (latest year)Rs 44 Cr
Cash from Investing Activity (latest year)Rs -21 Cr
Cash from Financing Activity (latest year)Rs -24 Cr
Net Cash Flow (latest year)Rs -1 Cr
Free cash flow (latest year)Rs 15 Cr
FCFE (approx.: FCF + change in debt)Rs 93 Cr
Cash from ops / profit, 5 years2.53x
Sales to cash flow4.31x
Statement figures
Net sales (TTM)Rs 325 Cr
Net sales (latest year)Rs 190 Cr
Sales (latest quarter)Rs 88 Cr
Operating profit excl. other income (latest year)Rs 47 Cr
Operating profit (latest quarter)Rs 30 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 105 Cr
PBDT (TTM)Rs 92 Cr
Profit before tax (TTM)Rs 49 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 36 Cr
Net profit (latest year)Rs 7 Cr
Net profit (latest quarter)Rs 13 Cr
Depreciation (TTM)Rs 43 Cr
Depreciation (latest quarter)Rs 11 Cr
Interest (TTM)Rs 14 Cr
Cost of goods sold (latest year)Rs 44 Cr
Total expenditure (latest year)Rs 143 Cr
Total income (latest year)Rs 191 Cr
Share capitalRs 7 Cr
ReservesRs 147 Cr
Shareholders' fundsRs 154 Cr
Total assetsRs 281 Cr
Net blockRs 195 Cr
Capital work in progressRs 2 Cr
ReceivablesRs 5 Cr
InventoryRs 6 Cr
Other liabilitiesRs 28 Cr
Shares outstanding (crore)5.20
Ownership
Promoter holding49.10% (+0.21 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SURAKSHA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -1.6% | -2.8% | +1.1 pts |
| 1 month | +2.7% | -6.8% | +9.5 pts |
| 3 months | +28.0% | -7.6% | +35.6 pts |
| 6 months | +53.6% | +0.4% | +53.2 pts |
| 1 year | +12.8% | -9.9% | +22.7 pts |
9 mutual fund schemes hold about ₹354 Cr.
Over three months 0 bought more and 7 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Nippon India Pharma Fund | 1.39% | 132 | -8% |
| Kotak Small Cap Fund | 0.63% | 123 | -1% |
| Aditya Birla SL ELSS Tax Saver Fund | 0.38% | 56 | -4% |
| Bandhan Innovation Fund | 0.51% | 13 | -21% |
| Aditya Birla SL Pharma & Healthcare Fund | 1.03% | 11 | -11% |
| JM Small Cap Fund | 0.85% | 8 | -29% |
| JM Value Fund | 0.83% | 7 | -17% |
| Bandhan Balanced Advantage Fund | 0.18% | 4 | -49% |
| Bandhan BSE Healthcare Index Fund | 0.04% | 0 | -8% |
Red flags
F-score 5 of 8| explain | Debt up, profit down Borrowings up 377% while net profit fell in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹88 Cr +20.5% vs Jun 2025.
Net profit ₹13 Cr +44.4%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | 32,737 | 58.2 | 28.0 % |
| Vijaya Diagnostic Centre Ltd | 15,192 | 81.0 | 20.5 % |
| Metropolis Healthcare Ltd | 11,665 | 56.0 | 17.8 % |
| Thyrocare Technologies Ltd | 8,708 | 48.2 | 35.4 % |
| Nephrocare Health Services Ltd | 6,671 | 78.4 | 15.3 % |
| Krsnaa Diagnostics Ltd | 1,791 | 18.1 | 12.7 % |
| 3B Blackbio DX Ltd | 1,396 | 25.1 | 25.5 % |
| One Global Service Provider Ltd | 1,046 | 14.1 | 87.0 % |
| Health X Platform Ltd | 923 | 0.03 % | |
| Gaudium IVF and Women Health Ltd | 830 | 35.9 | 29.3 % |
| Chandan Healthcare Ltd | 581 | 22.1 | 23.3 % |
| Pramodini Medicare Ltd | 259 | 14.9 | 41.8 % |
| Aspira Pathlab & Diagnostics Ltd | 148 | 2.84 % | |
| Choksi Laboratories Ltd | 132 | 69.2 | 9.44 % |
| Star Imaging and Path Lab Ltd | 131 | 6.80 | 26.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-15 | Dividend - Re 0.50 Per Share |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Suraksha Diagnostic Ltd?
Suraksha Diagnostic Ltd (SURAKSHA) has a market capitalisation of Rs 1,847 Cr. at the 2026-10-01 close.
What is the P/E ratio of Suraksha Diagnostic Ltd?
Suraksha Diagnostic Ltd trades at a P/E of 51.6 on trailing twelve-month profit, at the 2026-10-01 close.
What were Suraksha Diagnostic Ltd's latest quarterly results?
In the Jun 2026 quarter, Suraksha Diagnostic Ltd sales was Rs 88 Cr (+20.5% vs Jun 2025) and net profit was Rs 13 Cr.
What is the 52-week high and low of Suraksha Diagnostic Ltd?
The 52-week high is Rs 360.00 and the 52-week low is Rs 224.10.